GAIN THERAPEUTICS INC

NASDAQ: GANX (Gain Therapeutics, Inc.)

Last update: 23 hours ago

0.975

-0.07 (-6.25%)

Previous Close 1.04
Volume 521,050
Price / Book 4.54
52 Weeks Range
0.940 (-3%) — 4.34 (345%)
Diluted EPS (TTM) -0.830
Total Debt/Equity (MRQ) 10.50%
Current Ratio (MRQ) 2.22
Operating Cash Flow (TTM) -19.11 M
Levered Free Cash Flow (TTM) -10.84 M
Return on Assets (TTM) -97.10%
Return on Equity (TTM) -290.21%

AIStockmoo Score

-3.0
Value 30% -2.1
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Valuation History info NA
Low debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info
Earns below its cost of capital. Returns on capital falling. info
Timing 30% -4.1
From our AI technical analysis of the chart. info NA
Downtrend over the past year. Far below its 52-week high. info
Candle Patterns info NA
Trend for Your Holding Period info NA
Sentiment 20% 0.0
No recent price targets, so based on how targets have been revised. info
News Mood info NA
Smart Money 20% -1.4
Insider Activity info NA
Institutions net -0.52% of shares in their latest 13F filings: 23 holders increased, 18 decreased (quarter to 30 Sep 2026). info
Short interest +39.2% from 31 Aug to 30 Oct 2026, 5.5 days to cover (FINRA). info
Market and sector conditions are poor.
Market environment cautious. info
Sector lagging the market.
The pillars agree, so the score is strengthened.
Not in score
Price is low against its 52-week average. Down over 5 years. info
Trend down on all three terms. Short-term momentum falling. info
Price is near support. Levels trending down. info
Final Score -2.99

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bullish
Biotechnology (Global) Mixed Bullish
Stock Gain Therapeutics, Inc. Mixed Mixed

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
GANX - - - 4.54
TRML 1 B - - 4.76
TECH - 0.44% - 5.28
MLTX - - - 2.79
VKTX - - - 6.33
VSTM - - - 76.50

Select this tab to load the latest available analysis.

Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.

Sector Healthcare
Industry Biotechnology
Investment Style Small Core
% Held by Insiders 3.78%
% Held by Institutions 8.14%

Ownership

Name Date Shares Held
Cambridge Investment Research Advisors, Inc. 30 Sep 2026 566,645
Dme Capital Management, Lp 30 Jun 2026 566,130
Cresset Asset Management, Llc 30 Jun 2026 160,000

No data within this time range.

No data within this time range.

Institutions

Institutional ownership: 20.51%

Positions Holders Shares
Increased 23 865,600
Decreased 18 1,105,450
New 11 427,858
Sold out 6 422,295

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

Short Interest

Settlement Shares Days to cover
30 Oct 2026 3,891,227 5.5
15 Oct 2026 3,191,453 6.5
30 Sep 2026 3,056,188 5.9
15 Sep 2026 2,887,151 8.9
31 Aug 2026 2,795,819 7.7
14 Aug 2026 2,952,391 4.9

FINRA short interest via Nasdaq, reported twice a month.

1 Positive 0 Negative 2 Neutral
Date Type Details
16 Nov 2026 Yahoo Finance Gain Therapeutics (GANX) Upgraded to Buy: Here's What You Should Know
Gain Therapeutics (GANX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
10 Nov 2026 Yahoo Finance Gain Therapeutics Reports Financial Results for Third Quarter 2026 and Provides Corporate Update
BETHESDA, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the…
05 Nov 2026 Yahoo Finance Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences
BETHESDA, Md., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the presentation of two…
08 Oct 2026 Yahoo Finance Gain Therapeutics to Attend the 2026 Maxim Growth Summit
BETHESDA, Md., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small-molecule therapies, today announced it will participate in the…
01 Oct 2026 Yahoo Finance Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
MDS-UPDRS motor scores demonstrated stability to baseline recorded at study entry with no disease progression among the 12 evaluable participants who completed 12 months of daily oral administration of rexaceract by August 31, 2026 Participants with both high and low baseline levels of GluSph…
29 Sep 2026 Yahoo Finance Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders
BETHESDA, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced a poster presentation at…
17 Sep 2026 Yahoo Finance Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
BETHESDA, Md., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain” or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President…
25 Aug 2026 Yahoo Finance Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
BETHESDA, Md., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain” or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President…

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria